Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (20.0%)

Phase 24 (80.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

NCT00036257

Clinical Trials (5)

Showing 5 of 5 trials

NCT00036075Phase 2

Study Using CP-461 to Treat Advanced Prostate Cancer

Completed

NCT00036036Phase 2

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Completed

NCT00042055Phase 2

CP-461 for the Treatment of Crohn's Disease

Completed

NCT00060710Phase 2

CP-461 in the Treatment of Patients With Advanced Melanoma

Terminated

NCT00036257Phase 1

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5